NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $8.86 +0.49 (+5.85%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.21▼$8.8850-Day Range$5.76▼$8.8652-Week Range$3.19▼$13.20Volume54,348 shsAverage Volume393,972 shsMarket Capitalization$273.60 millionP/E RatioN/ADividend YieldN/APrice Target$22.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Acrivon Therapeutics alerts: Email Address Acrivon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside154.8% Upside$22.57 Price TargetShort InterestHealthy4.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.80Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.47) to ($2.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.36 out of 5 starsMedical Sector564th out of 936 stocksPharmaceutical Preparations Industry256th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.88% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Acrivon Therapeutics has recently decreased by 6.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 2.7 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.50% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.47) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Acrivon Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Acrivon Therapeutics Stock (NASDAQ:ACRV)Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Read More ACRV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRV Stock News HeadlinesJuly 16, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Increase in Short InterestMay 29, 2024 | globenewswire.comAcrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)May 14, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAcrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 11, 2024 | morningstar.comAcrivon Therapeutics Inc ACRVMay 9, 2024 | finance.yahoo.comWhile institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownershipJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.April 30, 2024 | msn.comLadenburg Thalmann Downgrades Acrivon Therapeutics (ACRV)April 26, 2024 | markets.businessinsider.comBuy Rating on Acrivon Therapeutics with Increased Target Price Amid Promising ACR-368 Trial DataApril 26, 2024 | morningstar.comAcrivon Therapeutics' shares climb 14% on plans to present cancer-test dataApril 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data ValidationApril 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market PotentialApril 24, 2024 | msn.comAcrivon Therapeutics’ shares climb 14% on plans to present cancer-test dataApril 24, 2024 | globenewswire.comAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventApril 20, 2024 | finance.yahoo.comAcrivon Therapeutics, Inc. (ACRV)April 16, 2024 | finance.yahoo.comAcrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316See More Headlines Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$22.57 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+154.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.65% Return on Assets-45.00% Debt Debt-to-Equity RatioN/A Current Ratio12.40 Quick Ratio12.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book1.65Miscellaneous Outstanding Shares30,880,000Free Float28,252,000Market Cap$273.60 million OptionableNot Optionable Beta0.86 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 61)Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Comp: $977.7kMs. Kristina Masson M.B.A. (Age 43)Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director Comp: $739.78kMs. Mary-Alice Miller J.D. (Age 50)Chief Legal Officer Comp: $587.11kMr. Rasmus Holm-Jorgensen (Age 52)Chief Financial Officer Comp: $1MDr. Eric J. Devroe Ph.D. (Age 45)Chief Operating Officer Comp: $614.78kMs. Katharine Peterson CPAVice President of Finance & AccountingDr. Adam D. Levy M.B.A.Ph.D., Senior VP and Head of Investor Relations & Corporate AffairsMr. Bruce CloseVice President of Quality & ComplianceMs. Parvin MiahVP & Head of Human ResourcesDr. Erick Gamelin M.D. (Age 66)Ph.D., Chief Development Officer Comp: $480.72kMore ExecutivesKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTCogent BiosciencesNASDAQ:COGTDianthus TherapeuticsNASDAQ:DNTHNuvation BioNYSE:NUVBEvolusNASDAQ:EOLSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 12,219 shares on 7/26/2024Ownership: 0.119%Baker BROS. Advisors LPBought 52,885 shares on 5/15/2024Ownership: 0.234%American International Group Inc.Bought 1,695 shares on 5/14/2024Ownership: 0.027%Vanguard Group Inc.Bought 31,208 shares on 5/10/2024Ownership: 2.241%Perceptive Advisors LlcBought 2,353,000 shares on 4/11/2024Total: $20.00 M ($8.50/share)View All Insider TransactionsView All Institutional Transactions ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $4.92 at the beginning of 2024. Since then, ACRV stock has increased by 80.1% and is now trading at $8.86. View the best growth stocks for 2024 here. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.16. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. Who are Acrivon Therapeutics' major shareholders? Acrivon Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.12%). Insiders that own company stock include Perceptive Advisors Llc, Ra Capital Management, LP and Ltd Chione. View institutional ownership trends. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACRV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts